Using data-driven phospho-proteomics approaches the CCS labs of Christian Huber and Fritz Aberger collaboratively determined the short-term effects of Hedgehog-modifying cancer drugs with yet unprecedented resolution at the post-translational level. The study sheds new light on the mechanism of action of clinically approved cancer drugs targeting oncogenic Hedgehog signaling and hints at potential new drug targets for improved therapeutic efficacy. The work by Scheidt et al. has been published in Cell Communication and Signaling. If interested in the entire study, follow this link to the open-access article.